Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First Safety First jobs

Executive Summary

As FDA expands its Safety First initiative, CDER is seeking candidates for three positions in the center's Office of New Drugs: a supervisory medical officer, a supervisory clinical analyst and a regulatory health project manager. Both supervisory positions will serve as full deputy to the division director and provide oversight, coordination and technical medical expertise on post-marketing safety. The project manager will manage all post-marketing safety activities in an OND division. The initiative is intended to strengthen and modernize FDA's internal policies and processes to manage significant drug safety issues (1"The Pink Sheet," March 3, 2008, p. 4)

You may also be interested in...

Safety First: FDA Unveils New Postmarketing Management Process For Safety

With FDA's latest new initiatives to address problems with postmarketing safety processes -Safety First/Safe Use - the agency is aiming at applying PDUFA-style management to postmarketing drug safety issues

New COVID Treatments Face FDA, Commercial Barriers Despite Ongoing Need

Sponsors want more endpoint clarity as current state of government pandemic response, along with scientific and regulatory hurdles, is constraining efforts to refill a shrinking COVID medicine cabinet and could create vulnerabilities for future pandemics.

China Planning To Ban Gene Editing Technology Exports

Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts